In line with this notion, combining RT with a TGF‐β‐targeting antibody (i.e., fresolimumab) in patients with metastatic BC was associated with systemic signs of tumor‐targeting immunity and a trend toward improved overall survival (despite a limited objective response rate) only in individuals receiving fresolimumab at 10 mg/Kg (Formenti et al, 2018). Here, TGFB1 is linked to neoplasm.